Aurinia Pharmaceuticals, Inc. (AUP) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1110640,
    "name": "Aurinia Pharmaceuticals, Inc.",
    "stock_name": "Aurinia Pharmaceuticals, Inc.",
    "full_name": "Aurinia Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/aurinia-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "15.31",
    "chg": -0.6,
    "chgp": "-3.77%",
    "dir": -1,
    "prev_price": "15.91",
    "mcapval": "1,619.04",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "CA05156V1022",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "904.59 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aurinia-pharmaceuticals-inc-1110640-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Aurinia Pharmaceuticals Hits New 52-Week High of $16.20",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurinia-pharmaceuticals-hits-new-52-week-high-of-1620-3674046",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuriniaPharmace_priceRelatedfactors_3674046.png",
        "date": "2025-11-05 16:48:31",
        "description": "Aurinia Pharmaceuticals, Inc. achieved a new 52-week high of USD 16.20, reflecting its strong performance in the pharmaceuticals sector. The company has seen significant stock growth, positive net sales, and profits, alongside a solid financial profile and high institutional ownership, reinforcing its market position."
      },
      {
        "title": "Aurinia Pharmaceuticals Hits Day High with 8.66% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurinia-pharmaceuticals-hits-day-high-with-866-surge-in-stock-price-3667397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuriniaPharmace_priceRelatedfactors_3667397.png",
        "date": "2025-11-03 17:44:49",
        "description": "Aurinia Pharmaceuticals has shown strong stock performance, gaining 8.66% on October 31, 2025, and outperforming the S&P 500 over the past year. The company reported a 12.08% increase in net sales and positive results for five consecutive quarters, reflecting robust operational strength and effective capital utilization."
      },
      {
        "title": "Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aurinia-pharmaceuticals-inc-overvalued-or-undervalued-3637781",
        "imagepath": "",
        "date": "2025-10-21 12:08:52",
        "description": "As of 17 October 2025, Aurinia Pharmaceuticals, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, which suggests that the stock may not be significantly undervalued despite its recent performance.\n\nIn comparison with peers, Aurinia's P/E ratio of 20.87 is higher than that of Rhythm Pharmaceuticals, Inc., which has a risky valuation with a P/E of -36.41, indicating a stark contrast in market perception. Additionally, Aurinia's EV to EBITDA ratio is more favorable than that of its peers, reflecting a relatively better valuation position. Notably, over the past year, Aurinia has outperformed the S&P 500, returning 60.86% compared to the index's 14.08%, reinforcing its attractiveness in the market despite a fair valuation...."
      },
      {
        "title": "Aurinia Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurinia-pharmaceuticals-valuation-grade-downgraded-from-very-attractive-to-fair-3640356",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AuriniaPharmace_valuationdot_3640356.png",
        "date": "2025-10-20 15:11:46",
        "description": "Aurinia Pharmaceuticals has recently adjusted its valuation, showcasing a P/E ratio of 19 and a price-to-book value of 3.16. The company has achieved a 60.86% return over the past year, outperforming the S&P 500, while its three-year return of 53.39% lags behind the index."
      },
      {
        "title": "Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aurinia-pharmaceuticals-inc-overvalued-or-undervalued-3634651",
        "imagepath": "",
        "date": "2025-10-20 12:26:16",
        "description": "As of 17 October 2025, the valuation grade for Aurinia Pharmaceuticals, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, indicating potential growth at a reasonable price.\n\nIn comparison to its peers, Aurinia's P/E ratio of 20.87 is notably higher than that of Rhythm Pharmaceuticals, Inc., which has a P/E of -36.41, highlighting the relative valuation strength of Aurinia. Additionally, the company’s ROCE of 99.51% and ROE of 16.33% suggest strong profitability compared to its industry. Over the past year, Aurinia has outperformed the S&P 500 with a return of 60.86% versus the index's 14.08%, reinforcing its current valuation stance...."
      },
      {
        "title": "Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aurinia-pharmaceuticals-inc-overvalued-or-undervalued-3632189",
        "imagepath": "",
        "date": "2025-10-19 12:03:48",
        "description": "As of 17 October 2025, Aurinia Pharmaceuticals, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued given its current P/E ratio of 19, a Price to Book Value of 3.16, and an EV to EBITDA ratio of 11.23. In comparison, its peer Rhythm Pharmaceuticals, Inc. has a significantly higher P/E of -36.41, while Merus NV shows a P/E of -13.18, indicating that Aurinia is relatively better positioned within its peer group.\n\nDespite the fair valuation, Aurinia has demonstrated strong performance with a year-to-date return of 28.62%, outperforming the S&P 500's return of 13.30% during the same period. However, over the longer term, the company's 5-year return of -25.44% starkly contrasts with the S&P 500's impressive 91.29% return, suggesting potential challenges ahead. Overall, Aurinia Pharmaceuticals is fairly valued in the current market context...."
      },
      {
        "title": "Aurinia Pharmaceuticals Experiences Revision in Score Amid Strong Financial Metrics and Market Position",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurinia-pharmaceuticals-valuation-grade-downgraded-from-attractive-to-fair-amid-price-decline-3617288",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AuriniaPharmace_valuationdot_3617288.png",
        "date": "2025-10-13 15:23:12",
        "description": "Aurinia Pharmaceuticals has adjusted its valuation, showcasing strong financial metrics such as a high return on capital employed and favorable P/E ratio compared to peers. The company has outperformed the S&P 500 over the past year, indicating its competitive strength in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aurinia-pharmaceuticals-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-adjustments-3600790",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AuriniaPharmace_technicaldot_3600790.png",
        "date": "2025-10-07 19:10:33",
        "description": "Aurinia Pharmaceuticals, Inc. has recently adjusted its technical trends, with its stock price at $11.32. Over the past year, the company has achieved a 58.99% return, significantly surpassing the S&P 500. Technical indicators suggest a bullish outlook, despite some short-term volatility in returns."
      },
      {
        "title": "Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-aurinia-pharmaceuticals-inc-technically-bullish-or-bearish-3599158",
        "imagepath": "",
        "date": "2025-10-07 12:20:04",
        "description": "As of 3 October 2025, the technical trend for Aurinia Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance weekly and bullish monthly. Daily moving averages are also mildly bullish. However, the RSI indicates no signal for both weekly and monthly periods, and Dow Theory shows no trend in either timeframe. \n\nIn terms of performance, Aurinia has outperformed the S&P 500 on a weekly basis with a return of 2.35% compared to 1.09%, but it has underperformed over the last month with a return of -8.71% versus 4.15%. Year-to-date, Aurinia is up 26.06% compared to the S&P 500's 14.18%, and over the past year, it has significantly outperformed with a return of 58.99% against 17.82%. However, over the longer terms of 3 years and 5 years, it has underperformed relative to the S&P 500. Overall, the cur..."
      }
    ],
    "total": 22,
    "sid": "1110640",
    "stock_news_url": "https://www.marketsmojo.com/news/aurinia-pharmaceuticals-inc-1110640"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Aurinia Pharmaceuticals Hits New 52-Week High of $16.20

2025-11-05 16:48:31

Aurinia Pharmaceuticals, Inc. achieved a new 52-week high of USD 16.20, reflecting its strong performance in the pharmaceuticals sector. The company has seen significant stock growth, positive net sales, and profits, alongside a solid financial profile and high institutional ownership, reinforcing its market position.

Aurinia Pharmaceuticals Hits Day High with 8.66% Surge in Stock Price

2025-11-03 17:44:49

Aurinia Pharmaceuticals has shown strong stock performance, gaining 8.66% on October 31, 2025, and outperforming the S&P 500 over the past year. The company reported a 12.08% increase in net sales and positive results for five consecutive quarters, reflecting robust operational strength and effective capital utilization.

Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-21 12:08:52

As of 17 October 2025, Aurinia Pharmaceuticals, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, which suggests that the stock may not be significantly undervalued despite its recent performance. In comparison with peers, Aurinia's P/E ratio of 20.87 is higher than that of Rhythm Pharmaceuticals, Inc., which has a risky valuation with a P/E of -36.41, indicating a stark contrast in market perception. Additionally, Aurinia's EV to EBITDA ratio is more favorable than that of its peers, reflecting a relatively better valuation position. Notably, over the past year, Aurinia has outperformed the S&P 500, returning 60.86% compared to the index's 14.08%, reinforcing its attractiveness in the market despite a fair valuation....

Aurinia Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-10-20 15:11:46

Aurinia Pharmaceuticals has recently adjusted its valuation, showcasing a P/E ratio of 19 and a price-to-book value of 3.16. The company has achieved a 60.86% return over the past year, outperforming the S&P 500, while its three-year return of 53.39% lags behind the index.

Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-20 12:26:16

As of 17 October 2025, the valuation grade for Aurinia Pharmaceuticals, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, indicating potential growth at a reasonable price. In comparison to its peers, Aurinia's P/E ratio of 20.87 is notably higher than that of Rhythm Pharmaceuticals, Inc., which has a P/E of -36.41, highlighting the relative valuation strength of Aurinia. Additionally, the company’s ROCE of 99.51% and ROE of 16.33% suggest strong profitability compared to its industry. Over the past year, Aurinia has outperformed the S&P 500 with a return of 60.86% versus the index's 14.08%, reinforcing its current valuation stance....

Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-19 12:03:48

As of 17 October 2025, Aurinia Pharmaceuticals, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued given its current P/E ratio of 19, a Price to Book Value of 3.16, and an EV to EBITDA ratio of 11.23. In comparison, its peer Rhythm Pharmaceuticals, Inc. has a significantly higher P/E of -36.41, while Merus NV shows a P/E of -13.18, indicating that Aurinia is relatively better positioned within its peer group. Despite the fair valuation, Aurinia has demonstrated strong performance with a year-to-date return of 28.62%, outperforming the S&P 500's return of 13.30% during the same period. However, over the longer term, the company's 5-year return of -25.44% starkly contrasts with the S&P 500's impressive 91.29% return, suggesting potential challenges ahead. Overall, Aurinia Pharmaceuticals is fairly valued in the current market context....

Aurinia Pharmaceuticals Experiences Revision in Score Amid Strong Financial Metrics and Market Position

2025-10-13 15:23:12

Aurinia Pharmaceuticals has adjusted its valuation, showcasing strong financial metrics such as a high return on capital employed and favorable P/E ratio compared to peers. The company has outperformed the S&P 500 over the past year, indicating its competitive strength in the Pharmaceuticals & Biotechnology sector.

Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-07 19:10:33

Aurinia Pharmaceuticals, Inc. has recently adjusted its technical trends, with its stock price at $11.32. Over the past year, the company has achieved a 58.99% return, significantly surpassing the S&P 500. Technical indicators suggest a bullish outlook, despite some short-term volatility in returns.

Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-07 12:20:04

As of 3 October 2025, the technical trend for Aurinia Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance weekly and bullish monthly. Daily moving averages are also mildly bullish. However, the RSI indicates no signal for both weekly and monthly periods, and Dow Theory shows no trend in either timeframe. In terms of performance, Aurinia has outperformed the S&P 500 on a weekly basis with a return of 2.35% compared to 1.09%, but it has underperformed over the last month with a return of -8.71% versus 4.15%. Year-to-date, Aurinia is up 26.06% compared to the S&P 500's 14.18%, and over the past year, it has significantly outperformed with a return of 58.99% against 17.82%. However, over the longer terms of 3 years and 5 years, it has underperformed relative to the S&P 500. Overall, the cur...

View All News